Viewing Study NCT05727618



Ignite Creation Date: 2024-05-06 @ 6:37 PM
Last Modification Date: 2024-10-26 @ 2:51 PM
Study NCT ID: NCT05727618
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-02-14
First Post: 2023-01-16

Brief Title: The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery
Sponsor: Qianfoshan Hospital
Organization: Qianfoshan Hospital

Study Overview

Official Title: The Effect of Pituitrin on Postoperative Outcomes in Patients With Pulmonary Hypertension Undergoing Cardiac Surgery a Randomized Controlled Study
Status: NOT_YET_RECRUITING
Status Verified Date: 2023-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is a parallel group single blind randomized controlled trial Patients with pulmonary hypertension who met the inclusion criteria and planned to undergo elective cardiac surgery under cardiopulmonary bypass from July 1 2022 to December 1 2024 in the Department of cardiac surgery of the First Affiliated Hospital of Shandong First Medical University were selected After removing the aortic blocking forceps the experimental group immediately injected the test drug pituitrin 004u kg h intravenously The control group was immediately injected with the corresponding dose of normal saline by intravenous pump The main outcome was the composite endpoint of all-cause mortality 30 days after operation or common complications after cardiac surgery stroke requiring mechanical ventilation for more than 48 hours deep sternal wound infection cardiac reoperation extracorporeal membrane oxygenation atrial fibrillation or acute renal injury
Detailed Description: Cardiac surgery is the most important treatment for serious coronary heart disease valvular heart disease congenital heart disease and other heart diseases Its postoperative mortality and serious complications have also been widely concerned especially in patients with pulmonary hypertension The persistent pulmonary hypertension and systemic vascular paralysis during the perioperative period are the main causes of early postoperative death and serious complications such as organ failureCatecholamine vasoactive drugs commonly used in cardiac surgery may aggravate the condition of pulmonary hypertension while the use of drugs to reduce pulmonary hypertension such as nitric oxide prostaglandins and phosphodiesterase inhibitors may worsen the state of systemic vascular paralysis

Vasopressin and oxytocin are two effective components in pituitrin and vasopressin is the main component that exerts strong vasoconstrictive effectVasopressin binds to receptors distributed in vascular smooth muscle pituitary and kidney and exerts its effects by regulating adenosine triphosphate sensitive K channel function nitric oxide production and enhancing vascular response to catecholamineIn addition oxytocin can also bind to the receptors distributed in the heart and vascular endothelium and play a role by releasing atrial natriuretic peptide and nitric oxideTherefore pituitrin can not only constrict systemic circulation vessels and increase systemic circulation pressure reduce pulmonary artery pressure and pulmonary vascular resistance but also protect the heart and kidney

Therefore this study intends to explore whether pituitrin has an impact on the prognosis of patients with pulmonary hypertension after cardiac surgery so as to provide reference for its clinical application

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None